FOCAL MEDICATION TITRATION SYSTEM

• US 20120136335A1
• Filed: 11/30/2010
• Published: 05/31/2012
• Est. Priority Date: 11/30/2010
• Status: Abandoned Application

• Current Assignee: Jonathan P. Hobbs
• Original Assignee: Jonathan P. Hobbs
• Inventors: Hobbs, Jonathan P.
• Application Number:
  US12/956,277
• Publication Number:
  US 20120136335A1
• Time in Patent Office: Days
• US Class Current: 604/503
• CPC Class Codes: A61B 5/369 Electroencephalography [EEG] devices for psychotechnics A61B5/16
• CPC Class Codes: A61B 5/4094 Diagnosing or monitoring seizure diseases, e.g. epilepsy
• CPC Class Codes: A61B 5/4839 combined with drug delivery
• CPC Class Codes: A61B 5/686 Permanently implanted devices, e.g. pacemakers, other stimulators, biochips A61B5/6861 takes precedence
• CPC Class Codes: A61B 5/6868 Brain
• CPC Class Codes: A61K 9/0009 involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis microelectromechanical systems A61K9/0097
• CPC Class Codes: A61K 9/0024 Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L
• CPC Class Codes: G16H 20/10 relating to drugs or medications, e.g. for ensuring correct administration to patients
• CPC Class Codes: G16H 20/70 relating to mental therapies, e.g. psychological therapy or autogenous training

Abstract

A system is provided for implantation into the skull of a patient including a device to detect the onset and/or existence of a neurological condition and deliver a medication to prevent the neurological condition, and/or to improve or sustain normal neurological function. Methods for utilizing the system and device are also provided.

Claims

1. An implantable device for treating a neurological episode comprising:

(a) a detection system having at least one sensor capable of detecting electromagnetic field signals;

(b) a processing system operationally coupled to the detection system for receiving and processing signals; and

(c) a therapy system operationally connected to the processing system;

wherein, the processing system;

(i) identifies signals received which are indicative of the neurological episode;

(ii) determines a medication need; and

(iii) activates the therapy system upon determination of a medication need; and

wherein, the therapy system is configured to deliver predetermined amounts of medication to a predetermined location at predetermined intervals upon the determination of a medication need.

2. The device of claim 1, wherein the device is configured to deliver a medication including an anti-seizure medication for treatment of epilepsy.

3. The device of claim 2, wherein the anti-seizure medication includes magnesium.

4. A method for treating an individual subject to chronic neurological abnormality comprising:

(a) implanting a treatment device under the subject'"'"'s scalp;

(b) detecting neurological electromagnetic field signals indicative of a neurological episode;

(c) providing a therapy to interrupt the neurological episode;

(d) obtaining further neurological electromagnetic field signals indicative of a resolution of the neurological episode; and

(e) interrupting the therapy upon obtaining signals indicative of the resolution of the episode;

wherein the steps of detecting, providing, obtaining, and interrupting are carried out by the device, and wherein the medication further comprises an anti-seizure medication.

5. The method of claim 4, wherein the anti-seizure medication includes magnesium ion.

6. The method of claim 4, wherein the anti-seizure medication is selected from the group consisting of:

1-[(2,6-difluorophenyl)methyl]-1H-1,2,3-triazole-4 carboxamide,

5H-dibenzo[b,f]azepine-5-carboxamide,

7-Chloro-1,5-dihydro-1-methyl-5-phenyl-1,5-benzodiazepine-2,4(3H)-dione,

5-(2-Chlorophenyl)-1,3-dihydro-7-nitro-1,4-benzodiazepin-2-one,

Sodium 2-propylpentanoate,

7-chloro-1-methyl-5-phenyl-3H-1,4-benzodiazepin-2-one,

sodium 5,5-diphenyl-2,4-imidazolidinedione,

3-ethyl-3-methylpyrrolidine-2,5-dione,

3-carbamoyloxy-2-phenylpropyl,

8-chloro-5-methyl-1-phenyl-1,5-benzodiazepine-2,4-dione,

2-[1-(aminomethyl)cyclohexyl]acetic acid,

(3R)-1-[4,4-bis(3-methylthiophen-2-yl)but-3-enyl]piperidine-3-carboxylic acid],

(2R)-2-(2-oxopyrrolidin-1-yl)butanamide,

5-(2-chlorophenyl)-7-nitro-2,3-dihydro-1,4-benzodiazepin-2-one,

3,5-diamino-6-(2,3-dichlorophenyl)-as-triazine,

6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine,

(−

)-(S)-α

-ethyl-2-oxo-1-pyrrolidine acetamide,

5-ethyl-5-phenyl-1,3-diazinane-2,4,6-trione,

(3S)-3-(aminomethyl)-5-methylhexanoic acid,

5-ethyl-5-phenyl-1,3-diazinane-4,6-dione,

2-[1-(aminomethyl)cyclohexyl]acetic acid,

5-oxo-6H-benzo[b][1]benzazepine-11-carboxamide,

5-ethyl-5-phenyl-1,3-diazinane-2,4,6-trione,

[(3R,3aS,6aR)-2,3,3a,4,5,6a-hexahydrofuro[5,4-b]furan-3-yl]N-[(2S,3R)-4-[(4-aminophenyl)sulfonyl-(2-methylpropyl)amino]-3-hydroxy-1-phenylbutan-2-yl]carbamate,

5,5-di(phenyl)imidazolidine-2,4-dione,

4-aminohex-5-enoic acid,

benzo[b][1]benzazepine-11-carboxamide,

(3R)-1-[4,4-bis(3-methylthiophen-2-yl)but-3-enyl]piperidine-3-carboxylic acid,

2,3;

4,5-Bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate,

5-oxo-6H-benzo[b][1]benzazepine-11-carboxamide,

2-propylpentanoic acid,

(R)-2-acetamido-N-benzyl-3-methoxypropionamide,

3-ethyl-3-methylpyrrolidine-2,5-dione,

1,2-benzoxazol-3-ylmethanesulfonamide, and

a combination thereof.

7. A method for providing chemotherapy comprising:

(a) identifying a tumor and its location; and

(b) delivering, a therapy, proximate the tumor, to interrupt the tumor'"'"'s growth;

wherein the therapy is delivered by a subdural device comprising;

(i) a processing system for determining a need for therapy; and

(ii) a therapy deliver system operationally connected to the processing system for delivering predetermined amounts of medication to predetermined sites;

wherein, upon determining the need for therapy, the processing system activates the therapy delivery system to provide the therapy which includes a medication.

8. The method of claim 7, wherein delivering, a therapy, proximate the tumor, is carried out according to a predetermined manner controlled by the processing system.

9. The method of claim 7, wherein delivering, a therapy, proximate the tumor, is carried out according to instructions currently determined and communicated to the therapy delivery system through the processing system.

10. The method of claim 7, wherein delivering, a therapy, proximate the tumor involves delivering a chemotherapy agent.

11. The method of claim 10, wherein the chemotherapy agent is selected form the group consisting of:

2-amino-4,6-dimethyl-3-oxo-N,N′

-bis[7,11,14-trimethyl-2,5,9,12,15-pentaoxo-3,10-di(propan-2-yl)-8-oxa-1,4,11,14-tetrazabicyclo[14.3.0]nonadecan-6-yl]phenoxazine-1,9-dicarboxamide,

(7S,9S)-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione,

2-amino-3-[4-[bis(2-chloroethyl)amino]phenyl]propanoic acid,

4-amino-1-[(2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one,

2,4,5-trioxa-1,3-diarsabicyclo[1.1.1]pentane,

Humanized anti-VEGF antibody,

1,3-bis(2-chloroethyl)-1-nitrosourea,

4-methylsulfonyloxybutyl methanesulfonate,

cis-diammine(cyclobutane-1,1-dicarboxylate-O,O′

)platinum(II),

1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea,

azane;

dichloroplatinum,

2H-1,3,2-Oxazaphosphorin-2-amine, N,3-bis(2-chloroethyl)-tetrahydro-, 2-oxide,

(7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione,

(5Z)-5-(dimethylaminohydrazinylidene)imidazole-4-carboxamide,

5-fluoro-1H-pyrimidine-2,4-dione,

(3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-[(2S,3R,4S,6R)-4-dimethylamino-3-hacyclotetradecane-2,10-dione,

[(2R,3S,4S,5R)-5-(6-amino-2-fluoropurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate,

4-amino-1-[(2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one,

Humanized anti-HER2 antibody,

hydroxyurea,

7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-8,10-dihydro-7H-tetracene-5,12-dione,

N,N-bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide irinotecan hydrochloride,

N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]furan-2-yl]quinazolin-4-amine,

(2R,3S,5R)-5-(6-amino-2-chloropurin-9-yl)-2-(hydroxymethyl)oxolan-3-ol,

(2S)-2-[[4-[(2,4-diaminopteridin-6-yl)methylmethylamino]benzoyl]amino]pentanedioic acid,

(1S)-5-Deoxy-1-C-[(2S,3S)-7-[[2,6-dideoxy-3-O-(2,6-dideoxy-β

-D-arabino-hexopyranosyl)-β

-D-arabino-hexopyranosyl]oxy]-3-[(O-2,6-dideoxy-3-C-methyl-β

-D-ribo-hexopyranosyl-(1→

3)-O-2,6-dideoxy-β

-D-lyxo-hexopyranosyl-(1→

3)-2,6-dideoxy-β

-D-arabino-hexopyranosyl)oxy]-1,2,3,4-tetrahydro-5,10-dihydroxy-6-methyl-4-oxo-2-anthracenyl]-1-O-methyl-D-threo-2-pentulose,

6-Amino-1,1a,2,8,8a,8b-hexahydro-8-(hydroxymethyl)-8a-methoxy-5-methyl-azirino[2′

,3′

;

3,4]pyrrolo[1,2-a]indole-4,7-dione carbamate (ester),

1,4-dihydroxy-5,8-bis[2-(2-hydroxyethylamino)ethylamino]anthracene-9,10-dione,

3′

,4′

-didehydro-4′

-deoxy-C′

-norvincaleukoblastine[R—

(R*,R*)-2,3-dihydroxybutanedioate,

Bis(2-chloroethyl)methylamine,

Nitrogen mustard,

Chimeric murine/human monoclonal anti-CD20 antibody,

2-amino-3,7-dihydropurine-6-thione,

5 beta,20-Epoxy-1,2a,4,7 beta,10 beta,13 alpha-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)—

N-benzoyl-3-phenylisoserine,

(2R,3S)—

N-carboxy-3-phenylisoserine,N-tert-butyl ester, 13-ester with 5β

-20-epoxy-1,2α

,4,7β

,10β

,13α

-hexahydroxytax-11-en-9-one 4-acetate 2-benzoate trihydrate,

(S)-10-[(dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H pyrano[3′

,4′

;

6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione monohydrochloride,

dimethyl(2β

,3β

,4β

,5α

,12β

,19α

)-15-[(5S,9S)-5-ethyl-5-hydroxy-9-(methoxycarbonyl)-1,4,5,6,7,8,9,10-octahydro-2H-3,7-methanoazacycloundecino[5,4-b]indol-9-yl]-3-hydroxy-16-methoxy-1-methyl-6,7-didehydroaspidospermidine-3,4-dicarboxylate,

methyl(1R,9R,10S,11R,12R,19R)-11-(acetyloxy)-12-ethyl-4-[(13S,15S,17S)-17-ethyl-17-hydroxy-13-(methoxycarbonyl)-1,11-diazatetracyclo[13.3.1.04,12.05,10]nonadeca-4(12),5,7,9-tetraen-13-yl]-8-formyl-10-hydroxy-5-methoxy-8,16diazapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2,4,6,13-tetraene-10-carboxylate,

4′

-demethyl-epipodophyllotoxin 9-[4,6-O—

(R)-ethylidene-beta-D-glucopyranoside], 4′

-(dihydrogen phosphate), and

pentyl[1-(3,4-dihydroxy-5-methyl-tetrahydrofuran-2-yl)-5-fluoro-2-oxo-1H pyrimidin-4-yl]aminomethanoate.

12. The method of claim 7, wherein delivering, a therapy, proximate the tumor involves delivering a medication including a nuclear factor ligand.